|Table of Contents|

Predictive value of Ki-67 index and serum CA15-3 level on the efficacy and prognosis of neoadjuvant endocrine therapy for estrogen receptor positive breast cancer patients

Journal Of Modern Oncology[ISSN:1672-4992/CN:61-1415/R]

Issue:
2024 23
Page:
4443-4448
Research Field:
Publishing date:

Info

Title:
Predictive value of Ki-67 index and serum CA15-3 level on the efficacy and prognosis of neoadjuvant endocrine therapy for estrogen receptor positive breast cancer patients
Author(s):
ZHANG Lingjie; GE Rui; CHENG Aiqun; HU Tianhua
Department of General Surgery,Fudan University Affiliated East China Hospital,Shanghai 200040,China.
Keywords:
breast cancer; estrogen receptor positive; neoadjuvant endocrine therapy; Ki-67 index; carbohydrate antigens 15-3
PACS:
R737.9
DOI:
10.3969/j.issn.1672-4992.2024.23.004
Abstract:
Objective:To explore the predictive value of Ki-67 index and serum carbohydrate antigen 15-3(CA15-3) level on the efficacy and prognosis of neoadjuvant endocrine therapy in patients with estrogen receptor(ER) positive breast cancer.Methods:90 ER-positive breast cancer patients who received neoadjuvant endocrine and surgical treatment and were admitted to the hospital from January 2016 to May 2022 were selected.Immunohistochemical SP staining was used to detect Ki-67 expression in cancer tissues,and serum CA15-3 levels were measured before and after neoadjuvant endocrine therapy.Logistic regression was used to analyze the relationship between Ki-67 and CA15-3 and the efficacy of neoadjuvant endocrine therapy in ER-positive breast cancer patients,and ROC curve was used to analyze the predictive value of the above indexes for efficacy.Disease-free survival(DFS) was recorded after 1-year follow-up.According to the Ki-67 index and serum CA15-3 level before treatment,the patients were divided into four groups.Group A had low Ki-67 expression and normal CA15-3,Group B had low Ki-67 expression and high CA15-3,Group C had high Ki-67 expression and normal CA15-3,and Group D had high Ki-67 expression and high CA15-3.The relationship between Ki-67 index and serum CA15-3 level and the prognosis of ER-positive breast cancer patients was analyzed.Results:Ki-67 index and serum CA15-3 level in breast cancer patients after neoadjuvant endocrine therapy were significantly lower than those before neoadjuvant endocrine therapy(P＜0.05).The Ki-67 index before treatment was independent influencing factor of pathological complete remission(pCR) after neoadjuvant endocrine therapy in ER positive breast cancer patients(P＜0.05).Ki-67 combined with CA15-3 predicted the area under the curve,sensitivity,and specificity of neoadjuvant endocrine therapy pCR in ER-positive breast cancer patients were 0.927,89.64%,and 85.26%,respectively,which were higher than single detection(P＜0.05).The 1-year DFS rates in groups A,B,C and D were 90.32%,64.29%,63.16% and 30.00%,respectively.The 1-year DFS rates in groups B,C and D were significantly lower than those in group A,and the 1-year DFS rates in group D were significantly lower than those in groups B and C(P＜0.05).The high expression of Ki-67 index and the high level of CA15-3 before treatment were independent risk factors for DFS in ER-positive breast cancer patients(P＜0.05).Conclusion:Ki-67 index and serum CA15-3 can effectively predict the efficacy and prognosis of neoadjuvant endocrine therapy for ER-positive breast cancer patients,and the combined detection is more effective.

References:

［1］中国抗癌协会乳腺癌专业委员会,吴炅.中国乳腺癌筛查与早期诊断指南［J］.中国癌症杂志,2022,32(4):363-372. Breast Cancer Professional Committee of China Anti Cancer Association，WU J.Guidelines for screening and early diagnosis of breast cancer in China［J］.Chinese Journal of Cancer,2022,32(4):363-372.
［2］SIRICO M,VIRGA A,CONTE B,et al.Neoadjuvant endocrine therapy for luminal breast tumors:State of the art,challenges and future perspectives［J］.Crit Rev Oncol Hematol,2023,181(2):103900.
［3］郑涛,王耕.激素受体阳性/HER2阴性乳腺癌新辅助内分泌治疗与新辅助化疗的疗效比较［J］.中国临床新医学,2021,14(7):700-704. ZHENG T,WANG G.Comparison of neoadjuvant endocrine therapy and neoadjuvant chemotherapy for hormone receptor positive/HER2 negative breast cancer［J］.China New Clinical Medicine,2021,14(7):700-704.
［4］RVU JM,KAND D,CHO J,et al.Prognostic impact of elevation of cancer antigen 15-3(CA15-3) in patients with early breast cancer with normal serum CA15-3 level［J］.J Breast Cancer,2023,26(2):126-135.
［5］倪健彬,王颖,吴祥虎.新辅助内分泌治疗与新辅助化疗治疗激素受体阳性/人表皮生长因子受体2阴性乳腺癌的疗效比较［J］.癌症进展,2024,22(1):96-99. NI JB,WANG Y,WU XH.Comparison the efficacy of neoadjuvant endocrine therapy and neoadjuvant chemotherapy for hormone receptor positive/human epidermal growth factor receptor 2 negative breast cancer［J］.Oncology Progress,2024,22(1):96-99.
［6］刘召弟,杨蔚,刘开惠,等.基于临床,病理及影像特征的列线图预测乳腺癌新辅助治疗后残余小病灶病理完全缓解［J］.中国医学计算机成像杂志,2023,29(1):32-38. LIU ZD,YANG W,LIU KH,et al.Nomogram based on clinical,pathologic and imaging features for predicting the pathologic complete response from minimal residual lesions after neoadjuvant treatment of breast cancer［J］.Chinese Computed Medical Imaging,2023,29(1):32-38.
［7］张维,龙松权,唐瑞骏.不同分子分型乳腺癌血清CYFRA21-1,HCY和CA15-3的表达差异及与术后复发,转移的关系［J］.检验医学与临床,2023,20(12):1686-1689. ZHANG W,LONG SQ,TANG RJ.Expression differences of serum CYFRA21-1,HCY and CA15-3 in different molecular subtypes of breast cancer and their relationships with postoperative recurrence and metastasis［J］.Laboratory Medicine and Clinic,2023,20(12):1686-1689.
［8］中国抗癌协会乳腺癌专业委员会.中国抗癌协会乳腺癌诊治指南与规范(2015版)［J］.中国癌症杂志,2015,25(9):692-754. Breast cancer Professional Committee of China Anti Cancer Association.Guidelines and Specifications for Diagnosis and Treatment of breast cancer of China Anti Cancer Association (2015 Edition)［J］.China Cancer Journal,2015,25(9):692-754.
［9］周玲,吴大广.GP化疗方案联合来曲唑内分泌治疗在乳腺癌中的应用价值［J］.中外医学研究,2023,21(2):9-13. ZHOU L,WU DG.Application value of GP chemotherapy regimen combined with letrozole endocrine therapy in breast cancer［J］.Chinese and Foreign Medical Research,2023,21(2):9-13.
［10］GOLDHIRSCH A,WOOD WC,COATES AS,et al.Strategies for subtypes-dealing with the diversity of breast cancer:Highlights of the St. Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2011［J］.Ann Oncol,2011,22(8):1736-1747.
［11］EISENHAUER EA,THERASSE P,BOGAERTS J,et al.New response evaluation criteria in solid tumours:Revised RECIST guideline (version 1.1)［J］.Eur J Cancer,2009,45(2):228-247.
［12］蒲星月,马原,钟志刚.2006-2020年中国女性乳腺癌死亡趋势分析-基于年龄-时期-出生队列模型［J］.卫生经济研究,2023,40(2):28-33. PU XY,MA Y,ZHONG ZG.Analysis of death trend of breast cancer among Chinese women from 2006 to 2020 based on age period birth cohort model［J］.Health Economics Research,2023,40(2):28-33.
［13］LI Z,WER H,LI S,et al.The role of progesterone receptors in breast cancer［J］.Drug Des Devel Ther,2022,16(26):305-314.
［14］BURSTEIN HJ,SOMERFIELD MR,BARTON DL,et al.Endocrine treatment and targeted therapy for hormone receptor-positive,human epidermal growth factor receptor 2-negative metastatic breast cancer:ASCO guideline update［J］.J Clin Oncol,2021,39(35):3959-3977.
［15］KHUSHK M,KHAN A,REHMAN A,et al.The role of tumor markers:Carcinoembryonic antigen and cancer antigen 15-3 in patients with breast cancer［J］.Cureus,2021,13(7):e16298.
［16］ZHAO YY,WANG SL,GAO XL.Value analysis of combined detection of serum ferritin,carcinoembryonic antigen and carbohydrate antigen 15-3 in diagnosis,recurrence and metastasis prediction of breast cancer［J］.Cancer Progress,2022,20(9):956-958.
［17］阿娜尔,刘云宏,陈美艳.乳腺癌新辅助内分泌治疗热点问题探讨［J］.中文科技期刊数据库（全文版）医药卫生,2021,12(6):24-26. ANAER,LIU YH,CHEN MY.Discussion on hot issues of neoadjuvant endocrine therapy for breast cancer［J］.Chinese Science and Technology Journal Database (full text),Medicine and Health,2021,12(6):24-26.
［18］郭楚楚,朱娟英.Ki-67在HR+/HER2-乳腺癌患者中的表达情况及预后价值［J］.浙江临床医学,2023,25(4):559-561. GUO CC,ZHU JY.Expression of Ki-67 in HR+/HER2- breast cancer patients and its prognostic value［J］.Zhejiang Clinical Medical Journal,2023,25(4):559-561.
［19］CHOI SB,PARK JM,AHN JH,et al.Ki-67 and breast cancer prognosis:Does it matter if Ki-67 level is examined using preoperative biopsy or postoperative specimen［J］.Breast Cancer Res Treat,2022,192(2):343-352.
［20］YE JS,ZHANG YJ,YE X，et al.Correlation analysis of the expression of Ki-67 and CDK4 and effect of neoadjuvant chemotherapy for advanced breast cancer［J］.Modern Oncology，2022，30（22）：4092-4096.
［21］MARTINS-BRANCO D,NADER-MARTA G,MOLINELLI C,et al.Ki-67 index after neoadjuvant endocrine therapy as a prognostic biomarker in patients with ER-positive/HER2-negative early breast cancer:A systematic review and meta-analysis［J］.Eur J Cancer,2023,194(4):113358.
［22］卢宇博,李咸君,张国强.影响乳腺癌新辅助化疗后病理完全缓解的临床因素分析［J］.现代肿瘤医学，2020，28（21）：3737-3740. LU YB,LI XJ,ZHANG GQ.Analysis of clinical factors influencing pCR of neoadjuvant chemotherapy for breast cancer［J］.Modern Oncology，2020，28（21）：3737-3740.
［23］钱晓燕,张频.人表皮生长因子受体2阳性乳腺癌新辅助治疗研究进展［J］.中国肿瘤临床与康复,2023,30(3):159-167. QIAN XY,ZHANG P.Research progress of neoadjuvant therapy for human epidermal growth factor receptor 2-positive breast cancer［J］.Chinese Journal of Clinical Oncology and Rehabilitation,2023,30(3):159-167.

Memo

Memo:
-
Last Update: 2024-11-01